Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target

With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now.

Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target

On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model after Boston Scientific re-entered the TAVR market through its stake in MiRus. Baird said the move is expected to provide modest accretion.

On May 18, BofA lowered its price goal on BSX to $68 from $105 and kept a Buy rating on the stock. The change followed meetings with 34 medtech companies in Las Vegas last week. The analyst said the firm updated several price targets to reflect what it called “the new reality of medtech valuations” amid a slower product cycle environment, concerns around the ACA and healthcare utilization, rising inflation after the war, and investor focus shifting toward “data centers over healthcare.”

Also on May 18, Boston Scientific announced a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank as part of its existing $5 billion buyback program. The company said it will initially receive around 30.4 million shares based on the May 15, 2026, closing stock price of $52.68. The final number of shares will depend on the stock’s average trading price during the term of the agreement.

Boston Scientific expects the ASR program to be completed by June 30, 2026. After the transaction, the company will still have $3 billion remaining under its share repurchase authorization. Management also said the buyback is expected to contribute about $0.02 to adjusted earnings per share for full-year 2026.

Boston Scientific Corporation (NASDAQ:BSX) develops, manufactures, and markets medical devices used across a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology, and Neuromodulation.

While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Dividend Penny Stocks to Buy Right Now and 10 Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1